Jonathan Chan

Advising a major pharmaceutical company in an arbitration related to the development of a blockbuster vaccine.
Advising a global technology client on the implications of the U.K. GDPR, ePrivacy Directive and Online Safety Act 2023 to assist with the strategic implementation of features on its online platforms.
Advising a major financial services institution in a trademark and breach of confidence action in the High Court of England and Wales.
Assisted a global life sciences client with coordinating high-value multi-jurisdictional patent litigation and providing advice on pan-European litigation strategy.
Represented a major life sciences client in a patent revocation dispute from pre-litigation strategy through to trial in the High Court of England and Wales.
Advised a life sciences client on its pan-European patent litigation in parallel with EPO opposition proceedings.
Acted for a major asset management firm with numerous IP-led transactions and provided support in the due diligence process.
Advised a multinational pharmaceutical client in a trademark clearance project in the U.K.
Acted for an international luxury fashion brand in the protection of its trademarks.
Provided copyright and trade mark advice to a number of pro bono clients.

“Case Comments: UK Supreme Court Rules that an AI System Cannot Be an Inventor of a Patent: Implications of the Thaler v Comptroller Decision for the Life Sciences Industry.” Bio-Science Law Review, Volume 19, Issue 5, Co-Author
SEPTEMBER 14, 2026

Jonathan ChanJonathanChan